EGFR and non-small cell lung carcinoma: Compared with traditional platinum-based combination chemotherapy, EGFR TKI unprecedentedly brought a better clinical benefit and quickly laid its own position in treating advanced non-small cell lung cancer patients with EGFR mutation.